Agenda
The 5rd International Practical Research Conference: Hematology. Innovations. Clinical Practice
For in-person participants: Irkutsk, 15 Chkalov St., “Irkutsk City Center” Hotel, Conference Hall
September 26, 2025
09:00–09:30 – Registration
09:30–09:40 – Opening of the conference. Welcome remarks
Moderators: S.V. Syomochkin, O.V. Pirogova, N.O. Saraeva
09:40–10:10 – Bispecific antibodies in the treatment of multiple myeloma: teclistamab as a new standard for patients with refractory MM – S.V. Syomochkin (Moscow). Supported by Johnson & Johnson LLC.
10:10–10:40 – First-line therapy for multiple myeloma: the role of Darzalex in modern treatment regimens and the advantages of the subcutaneous formulation – A.D. Garifullin (St. Petersburg). Supported by Johnson & Johnson LLC
10:40–11:20 – The role of CAR-T immunotherapy in B-cell leukemia and lymphoma – Yu Hongjuan (Harbin, China).
11:20–11:35 – Molecular genetic mutations in multiple myeloma patients in the Irkutsk Region detected by FISH – E.A. Shmakova (Irkutsk). Supported by ISMU.
11:35–12:15 – Precise typing and advances in the treatment of DLBCL – Huang Dayun (Beijing, China).
12:15–12:45 – AL amyloidosis: a multidisciplinary approach to patient management – O.V. Pirogova (St. Petersburg). Supported by Johnson & Johnson LLC.
12:45–13:05 – The role of daratumumab in multiple myeloma therapy: past, present, and future – N.O. Saraeva (Irkutsk). Supported by BIOCAD.
13:05–13:25 – Evidence and clinical experience of danicopan in patients with PNH with suboptimal response to C5 inhibitor therapy – A.D. Kulagin (St. Petersburg). Supported by AstraZeneca.
13:25–13:45 – Frequency and structure of non-malignant hematological pathology in the Irkutsk Region – N.O. Saraeva (Irkutsk). Supported by ISMU.
13:45–14:20 – Break
Moderators: E.V. Morozova, N.O. Saraeva
14:20–14:40 – Comprehensive approach to rehabilitation of oncohematology patients – M.S. Voytko (Novosibirsk).
14:40–15:20 – Extramedullary relapse of acute lymphoblastic leukemia treated with CAR-T as a bridge to unrelated umbilical cord blood transplantation – Li Huibo (Harbin, China).
15:20–15:40 – STAMP inhibitors in the treatment of CML – E.V. Morozova (St. Petersburg). Supported by R-Pharm JSC.
15:40–16:00 – Fixed-duration therapy for CLL: new opportunities – N.B. Mikhailova (St. Petersburg). Supported by AstraZeneca.
16:00–16:20 – Current clinical guidelines for PNH in 2025: updates and additions – N.O. Saraeva (Irkutsk). Supported by Sobi. CME credits not awarded.
16:20–16:40 – Hematology practice in the Irkutsk Regional Perinatal Center – E.A. Tarkhova (Irkutsk). Supported by ISMU.
16:40–17:00 – Physical activity opportunities in patients receiving emicizumab – N.O. Saraeva (Irkutsk). Supported by Roche.
17:00–17:20 – Discussion
September 27, 2025
Moderators: S.V. Syomochkin, O.V. Petrova, N.O. Saraeva
10:00–10:15 – Global experience of teclistamab in refractory MM: review of real-world clinical practice studies – S.V. Syomochkin (Moscow). Supported by Johnson & Johnson LLC.
10:15–10:25 – Discussion / clinical case Q&A
10:25–10:40 – Experience with the fixed combination of venetoclax and acalabrutinib in CLL: clinical case – N.B. Mikhailova (St. Petersburg). Supported by AstraZeneca.
10:40–10:50 – Discussion / clinical case Q&A
10:50–11:10 – Clinical case: use of STAMP inhibitor in CML – E.V. Morozova (St. Petersburg). Supported by R-Pharm JSC.
11:10–11:15 – Discussion / clinical case Q&A
11:15–11:30 – Clinical cases of successful treatment of extravascular hemolysis in PNH – A.D. Kulagin (St. Petersburg). Supported by AstraZeneca.
11:30–11:40 – Discussion / clinical case Q&A
11:40–12:10 – Break
Moderators: E.V. Morozova, A.D. Garifullin, N.O. Saraeva
12:10–12:25 – Experience with emicizumab in patients with hemophilia A: clinical cases – N.O. Saraeva (Irkutsk). Supported by Roche.
12:25–12:35 – Discussion / clinical case Q&A
12:35–12:50 – Clinical case of successful use of subcutaneous Darzalex in MM – A.D. Garifullin (St. Petersburg). Supported by Johnson & Johnson LLC.
12:50–13:00 – Discussion / clinical case Q&A
13:00–13:15 – Modern opportunities in the treatment of ITP: clinical case – N.O. Saraeva (Irkutsk).
13:15–13:25 – Discussion / clinical case Q&A
13:25–13:40 – Clinical cases of AL amyloidosis: the hematologist’s perspective – O.V. Pirogova (St. Petersburg). Supported by Johnson & Johnson LLC.
13:40–13:50 – Discussion / clinical case Q&A
13:50–14:20 – Closing session: Practical aspects of treating MM, CLL, CML, AL amyloidosis, PNH, hemophilia, and ITP.
Speakers
Natalia O. Saraeva, MD, Dr. Sci. Med.
Chief Hematologist, Ministry of Health of the Irkutsk Region;
Professor of Department of Hospital Therapy,
Irkutsk State Medical University (Irkutsk, Russia)
Sergey V. Syomochkin, MD, Dr. Sci. Med.
Head of the Group of High-Dose Chemotherapy and Bone Marrow Transplantation, Department of Drug Therapy of Tumors, P.A. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiology Center;
Professor of Department of Oncology, Hematology, and Radiation Therapy,
Pirogov Russian National Research Medical University (Moscow, Russia)
Natalia O. Saraeva, MD, Dr. Sci. Med.
Chief Hematologist, Ministry of Health of the Irkutsk Region;
Professor of Department of Hospital Therapy,
Irkutsk State Medical University (Irkutsk, Russia)
Sergey V. Syomochkin, MD, Dr. Sci. Med.
Head of the Group of High-Dose Chemotherapy and Bone Marrow Transplantation, Department of Drug Therapy of Tumors, P.A. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiology Center;
Professor of Department of Oncology, Hematology, and Radiation Therapy,
Pirogov Russian National Research Medical University (Moscow, Russia)
Andrey D. Garifullin, MD, PhD
Head of Department of Hematology, Chemotherapy, and Bone Marrow Transplantation with Intensive Care Unit, Russian Research Institute of Hematology and Transfusiology, Federal Medical-Biological Agency of Russia (St. Petersburg, Russia)
Olga V. Pirogova, MD, PhD
Senior Researcher of R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov First St. Petersburg State Medical University (St. Petersburg, Russia)
Andrey D. Garifullin, MD, PhD
Head of Department of Hematology, Chemotherapy, and Bone Marrow Transplantation with Intensive Care Unit, Russian Research Institute of Hematology and Transfusiology, Federal Medical-Biological Agency of Russia (St. Petersburg, Russia)
Olga V. Pirogova, MD, PhD
Senior Researcher of R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov First St. Petersburg State Medical University (St. Petersburg, Russia)
Elena V. Morozova, MD, PhD
Associate Professor of Department of Hematology, Transfusiology and Transplantology with the Course of Pediatric Oncology, Faculty of Postgraduate Education named after Prof. B.V. Afanasyev;
Head, Department of Oncology, Hematology and Transplantology for Adolescents and Adults, R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov First St. Petersburg State Medical University (St. Petersburg, Russia)
Natalia B. Mikhailova, MD, PhD
Associate Professor of Department of Hematology, Transfusiology and Transplantology with the Course of Pediatric Oncology, Faculty of Postgraduate Education named after Prof. B.V. Afanasyev;
Head, Department of Oncology (Chemotherapy and BMT), R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov First St. Petersburg State Medical University (St. Petersburg, Russia)
Elena V. Morozova, MD, PhD
Associate Professor of Department of Hematology, Transfusiology and Transplantology with the Course of Pediatric Oncology, Faculty of Postgraduate Education named after Prof. B.V. Afanasyev;
Head, Department of Oncology, Hematology and Transplantology for Adolescents and Adults, R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov First St. Petersburg State Medical University (St. Petersburg, Russia)
Natalia B. Mikhailova, MD, PhD
Associate Professor of Department of Hematology, Transfusiology and Transplantology with the Course of Pediatric Oncology, Faculty of Postgraduate Education named after Prof. B.V. Afanasyev;
Head, Department of Oncology (Chemotherapy and BMT), R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov First St. Petersburg State Medical University (St. Petersburg, Russia)
Alexander D. Kulagin, MD, Dr. Sci. Med.
Head of Department of Hematology, Transfusiology and Transplantology with the Course of Pediatric Oncology, Faculty of Postgraduate Education named after Prof. B.V. Afanasyev; Director of R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov First St. Petersburg State Medical University (St. Petersburg, Russia)
Maria S. Voytko, MD, PhD
Assistant Professor of Department of Therapy, Hematology and Transfusiology, Novosibirsk State Medical University (Novosibirsk, Russia)
Alexander D. Kulagin, MD, Dr. Sci. Med.
Head of Department of Hematology, Transfusiology and Transplantology with the Course of Pediatric Oncology, Faculty of Postgraduate Education named after Prof. B.V. Afanasyev; Director of R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov First St. Petersburg State Medical University (St. Petersburg, Russia)
Maria S. Voytko, MD, PhD
Assistant Professor of Department of Therapy, Hematology and Transfusiology, Novosibirsk State Medical University (Novosibirsk, Russia)
Ekaterina A. Shmakova, MD
Clinical Laboratory Diagnostics Physician of Irkutsk Regional Clinical Hospital(Irkutsk, Russia)
Ekaterina A. Tarkhova, MD
Hematologist of Perinatal Center, Irkutsk Regional Clinical Hospital (Irkutsk, Russia)
Ekaterina A. Shmakova, MD
Clinical Laboratory Diagnostics Physician of Irkutsk Regional Clinical Hospital(Irkutsk, Russia)
Ekaterina A. Tarkhova, MD
Hematologist of Perinatal Center, Irkutsk Regional Clinical Hospital (Irkutsk, Russia)
Li Huibo, MD
Deputy Head of Department of Hematopoietic Transplantation, Intensive Care and Translational Medicine, The First Affiliated Hospital of Harbin Medical University (Harbin, China)
Prof. Huang Dayong,
Chief Physician, hematologist, Beijing Friendship Hospital (Sino-Russian Friendship Hospital, the first Class A tertiary hospital in Beijing and China) (Beijing, China)
Prof. Yu Hongjuan, MD
Head of Department of Hematology; Chief of Lymphoma Department, The First Affiliated Hospital of Harbin Medical University (Harbin, China)
Li Huibo, MD
Deputy Head of Department of Hematopoietic Transplantation, Intensive Care and Translational Medicine, The First Affiliated Hospital of Harbin Medical University (Harbin, China)
Prof. Yu Hongjuan, MD
Head of Department of Hematology; Chief of Lymphoma Department, The First Affiliated Hospital of Harbin Medical University (Harbin, China)
Prof. Huang Dayong,
Chief Physician, hematologist, Beijing Friendship Hospital (Sino-Russian Friendship Hospital, the first Class A tertiary hospital in Beijing and China) (Beijing, China)
Organized by
Partners
Previous agendas
- of the 4th International Practical Research Conference: Hematology. Innovations. Clinical Practice. 22 September 2023 Irkutsk
- 3rd International Practical Research Conference: Hematology. Innovations. Clinical Practice. Round table discussion – Chronic Lymphocytic Leukemia: Past, Present and Future. 26 November 2021 Irkutsk
- 3rd International Practical Research Conference: Hematology. Innovations. Clinical Practice. Round table discussion: Challenging issues of hemostasis in the present-day clinical practice. September 24 2021, Irkutsk
- 3rd International Practical Research Conference: Hematology. Innovations. Clinical Practice. Round table discussion: Current approaches to treatment of multiple myeloma. July 29 2021, Irkutsk